HomeHealthcare & Life SciencesPharmaceuticals Charles Bonnet Syndrome Market

North America Charles Bonnet Syndrome Market Size & Outlook, 2026-2034


North America Charles Bonnet Syndrome Market Insights

  • As per Reed Intelligence insights, North America’s Charles Bonnet Syndrome Market was valued at USD 93.06 Million in 2025 and is anticipated to expand to USD 194.95 Million by 2034.
  • From 2026 to 2034, the market is anticipated to expand at a CAGR of 8.56%.
  • Within By Treatment Type, Pharmacological Therapy accounted for the largest market size in 2025.
  • During the forecast period, Behavioral Therapy is anticipated to remain the highest-growth segment within the By Treatment Type category.

Other Key Findings


  • North America represented 30.02% of the global Charles Bonnet Syndrome Market size in 2025.
  • By 2034, United States is estimated to hold the largest position in the global market in terms of size.
  • Canada is estimated to remain the fastest-growing market in North America, advancing to USD 49.79 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 93.06 Million
Market Size In 2034 USD 194.95 Million
Largest segment Pharmacological Therapy
Units Revenue in USD Million
CAGR 8.56% (2026-2034)
Segmnetation Covered
North America
  1. United States
  2. Canada
By Treatment Type
  1. Pharmacological Therapy
  2. Digital Therapeutics
  3. Behavioral Therapy
By Diagnosis Type
  1. Clinical Diagnosis
  2. AI-Assisted Diagnosis
By End-Use
  1. Hospitals
  2. Clinics
  3. Home Care Settings
By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports